Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Placebo-controlled, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of An Adjuvanted Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years

NCT02052726 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02052726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02052726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Placebo-controlled, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of An Adjuvanted Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
January 22, 2014
Completion date
May 5, 2015
Enrollment
184 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile